Hørsholm, Denmark (24 November 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that its executive management will host a live webcast on 30 November 2020, at 5:00 p.m. CET to discuss the company’s third quarter 2020 results and provide a business and financial update. The webcast will follow the publication of Allarity Therapeutic’s Q3 2020 report, also scheduled for release on 30 November 2020.
Interested parties may register for the event via the Events and Presentations section of the Allarity Therapeutics website at https://allarity.com/investors/events-and-presentations. Please connect to the web-conference application prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to access the webcast.
- General business update by CEO Steve Carchedi
- Financial update by CFO Jens Knudsen
Pre-submitted questions will be prioritized for the Q&A. To pre-submit a question, please email it to email@example.com, no later than 3 p.m. CET on 30 November.
Online webcast/conference call:
Attendees are encouraged to pre-register in order to be able to watch the presentation slides using this link:
Attendees who would wish to call in may use the following:
- Attendee Dial-in Number: +1 (312) 248-9348
- Attendee Dial-in ID Number: 895344
- Attendee Dial-in Passcode: 4683
For further information, please contact:
Carrotize PR & Communications
+45 6062 9390
About Allarity Therapeutics
Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: Stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; Dovitinib, a pan-TKI in post-Phase 3 for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and Irofulven, a DNA damaging agent in Phase 2 for prostate cancer.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Svensk Kapitalmarknadsgranskning AB, Email: firstname.lastname@example.org. Tel: +46 11 32 30 732